World's Best Scientists 2026 revealed!
Ursula A. Matulonis

Ursula A. Matulonis

D-Index & Metrics

Medicine

D-Index
112
Citations
52802
World Ranking
5105
National Ranking
2760

Overview

Ursula A. Matulonis is affiliated with Harvard University in the United States. Their research primarily focuses on medicine, with a substantial contribution to biochemistry, genetics, and molecular biology. Within these broad fields, their work concentrates notably on oncology, reproductive medicine, and molecular biology, with additional involvement in pulmonary and respiratory medicine as well as obstetrics and gynecology.

The main topics addressed in their research include ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, endometrial and cervical cancer treatments, advanced breast cancer therapies, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, and cancer mechanisms and therapy.

They have published extensively in various scientific journals, with frequent contributions to:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • Gynecologic Oncology Reports
  • Clinical Cancer Research

Ursula A. Matulonis has collaborated with several frequent coauthors, including:

  • Panagiotis A. Konstantinopoulos
  • Joyce F. Liu
  • Susana M. Campos
  • Alexi A. Wright
  • Neil S. Horowitz

Their recent papers include:

  • A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors, 2020, Nature Medicine
  • A single-cell landscape of high-grade serous ovarian cancer, 2020, Nature Medicine
  • Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer, 2020, Nature Communications
  • Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study, 2023, Journal of Clinical Oncology
  • Clinical and translational advances in ovarian cancer therapy, 2023, Nature Cancer

Best Publications

  • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Mansoor R. Mirza;Bradley J. Monk;Jørn Herrstedt;Amit M. Oza

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

    Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek

  • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

    Stephen A. Cannistra;Ursula A. Matulonis;Richard T. Penson;Julie Hambleton

  • Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health

    Alexi A. Wright;Nancy L. Keating;Tracy A. Balboni;Ursula A. Matulonis

  • A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

    Michal Slyper;Caroline B. M. Porter;Orr Ashenberg;Julia Waldman

  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.

    Kyle C. Strickland;Brooke E Howitt;Sachet A Shukla;Scott J. Rodig

  • Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases

    Mariana C. Castells;Nichole M. Tennant;David E. Sloane;F. Ida Hsu

  • Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

    Brooke Elizabeth Howitt;Sachet Shukla;Lynette Marie Sholl;Lauren Lee Ritterhouse

  • Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Triona Ni Chonghaile;Kristopher A. Sarosiek;Thanh Trang Vo;Jeremy A. Ryan

  • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

    Joyce F. Liu;William T. Barry;Michael Birrer;Jung Min Lee

  • Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

    Stan B. Kaye;Jan Lubinski;Ursula Matulonis;Joo Ern Ang

  • Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    U.A. Matulonis;R. Shapira-Frommer;A.D. Santin;A.S. Lisyanskaya

  • Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer

    Harold J. Burstein;Irene Kuter;Susana M. Campos;Rebecca S. Gelman

  • Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

    Jonathan A Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Kathleen N Moore;Angeles Alvarez Secord;Melissa A Geller;David Scott Miller

  • PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.

    Liya Ding;Hye-Jung Kim;Qiwei Wang;Michael Kearns

  • Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

    Panagiotis A. Konstantinopoulos;Steven Waggoner;Gregory A. Vidal;Monica Mita

  • Institutional implementation of clinical tumor profiling on an unselected cancer population

    Lynette M. Sholl;Khanh Do;Priyanka Shivdasani;Ethan Cerami

Frequent Co-Authors

Michael J. Birrer
Michael J. Birrer University of Arkansas for Medical Sciences
Ross S. Berkowitz
Ross S. Berkowitz Harvard Medical School
Kathleen N. Moore
Kathleen N. Moore University of Oklahoma Health Sciences Center
Hang Lee
Hang Lee Harvard University
Ronny Drapkin
Ronny Drapkin University of Pennsylvania
David M. O'Malley
David M. O'Malley The Ohio State University
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Gini F. Fleming
Gini F. Fleming University of Chicago
Alan D. D'Andrea
Alan D. D'Andrea Dana-Farber Cancer Institute
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in studying Medicine in the USA, there are many alternative degrees and career paths in the healthcare field to consider. For those looking for accessible options, there are easy nursing schools to get into that offer supportive admission processes and can be a great starting point for a healthcare career.

For students who prefer remote study or need flexible schedules, you might explore online medical billing and coding schools that accept fafsa. These programs open doors to in-demand roles in healthcare administration and records management, while also allowing you to apply for federal financial aid.

Some programs lower barriers further, like those nursing school that does not require teas test, removing common entrance exam hurdles for applicants and streamlining the pathway to a nursing degree.

Additionally, for career-driven students, there are healthcare administration degree programs that can be completed online in an accelerated format, providing leadership training for administrative roles within the healthcare sector.

Best Scientists Citing Ursula A. Matulonis

Trending Scientists

Recently Published Articles